{"id":"pirfenidone-oral-product","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Dyspnea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Pirfenidone works by binding to the TGF-β receptor, preventing the activation of downstream signaling pathways that lead to fibrosis. This results in the inhibition of fibroblast proliferation and the reduction of extracellular matrix deposition. Additionally, pirfenidone has been shown to have anti-inflammatory and antioxidant properties.","oneSentence":"Pirfenidone is an antifibrotic agent that inhibits the production of transforming growth factor-beta (TGF-β), a key cytokine involved in fibrosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:14.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Idiopathic pulmonary fibrosis"}]},"trialDetails":[{"nctId":"NCT05674994","phase":"PHASE3","title":"Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2023-10-26","conditions":"Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":110},{"nctId":"NCT06871904","phase":"PHASE1, PHASE2","title":"Fibrosis-Modulating Effects of Metformin and Pirfenidone in Oral Submucous Fibrosis","status":"COMPLETED","sponsor":"Ziauddin University","startDate":"2025-04-07","conditions":"Oral Submucous Fibrosis","enrollment":45},{"nctId":"NCT05195918","phase":"PHASE1","title":"Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hal Chapman","startDate":"2023-08-24","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":50},{"nctId":"NCT06070610","phase":"PHASE1","title":"A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-11-08","conditions":"Healthy","enrollment":14},{"nctId":"NCT07015398","phase":"PHASE1","title":"A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants","status":"COMPLETED","sponsor":"Trevi Therapeutics","startDate":"2025-06-30","conditions":"Healthy Participants","enrollment":132},{"nctId":"NCT07161791","phase":"PHASE1, PHASE2","title":"Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2025-09-15","conditions":"Breast Cancer, Triple Negative Breast Cancer (TNBC)","enrollment":12},{"nctId":"NCT06569381","phase":"PHASE1","title":"Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets in Healthy Subjects Under Fasting and Fed Conditions","status":"COMPLETED","sponsor":"Overseas Pharmaceuticals, Ltd.","startDate":"2024-09-18","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":18},{"nctId":"NCT04971746","phase":"PHASE1","title":"Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2021-07-19","conditions":"Healthy","enrollment":58},{"nctId":"NCT05713292","phase":"PHASE3","title":"Pirfenidone in Adult Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2022-12-01","conditions":"COVID-19 Pneumonia","enrollment":168},{"nctId":"NCT05826821","phase":"","title":"Biomarkers in HF: Circulating Biomarkers of Fibrosis and Cardiovascular Disease","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2017-03-02","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":107},{"nctId":"NCT05531955","phase":"PHASE2","title":"Pirfenidone Treat Myocardial Fibrosis After Acute Myocardial Infarction","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-08-05","conditions":"Myocardial Fibrosis","enrollment":100},{"nctId":"NCT04939467","phase":"PHASE1","title":"Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Blade Therapeutics","startDate":"2021-10-15","conditions":"Drug Drug Interaction","enrollment":86},{"nctId":"NCT04888715","phase":"PHASE1","title":"To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-07-23","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":48},{"nctId":"NCT03092102","phase":"PHASE1","title":"The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2017-05-20","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":136},{"nctId":"NCT02932566","phase":"PHASE2","title":"The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2017-03-02","conditions":"Cardiac Failure","enrollment":129},{"nctId":"NCT03530150","phase":"PHASE2","title":"Pirfenidone and Its Role in Burn Wound Healing","status":"COMPLETED","sponsor":"Universidad Autonoma de Nuevo Leon","startDate":"2017-01-01","conditions":"Second-degree Burn","enrollment":8},{"nctId":"NCT00076102","phase":"PHASE2","title":"Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-07-21","conditions":"Neurofibromatosis 1, Neurofibroma, Plexiform","enrollment":36},{"nctId":"NCT03068234","phase":"PHASE2, PHASE3","title":"Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-05","conditions":"Systemic Sclerosis","enrollment":72},{"nctId":"NCT02161952","phase":"PHASE2","title":"Pirfenidone, an Antifibrotic and Antiinflammatory Drug","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2005-05","conditions":"Fibrosis, Hepatitis C Chronic","enrollment":150},{"nctId":"NCT00001959","phase":"PHASE2","title":"Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1999-12","conditions":"Fibrosis, Focal Glomerulosclerosis, Kidney Failure","enrollment":21},{"nctId":"NCT00063583","phase":"PHASE1, PHASE2","title":"Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes","status":"COMPLETED","sponsor":"Sharma, Kumar, M.D.","startDate":"2003-06","conditions":"Diabetes Mellitus, Diabetic Nephropathy","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kitoscell"],"phase":"phase_3","status":"active","brandName":"Pirfenidone Oral Product","genericName":"Pirfenidone Oral Product","companyName":"Capital Medical University","companyId":"capital-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pirfenidone is an antifibrotic agent that inhibits the production of transforming growth factor-beta (TGF-β), a key cytokine involved in fibrosis. Used for Idiopathic pulmonary fibrosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}